NewAmsterdam says former Amgen cardio drug reduces heart disease risk factor

A Dutch biotech has proved its resurrected Amgen drug is capable of significantly lowering “bad” cholesterol in a handful of mid-stage trials in recent years, and a new analysis suggests the therapy also lowers a key risk factor for heart disease.

NewAmsterdam Pharma said Tuesday that a 10 mg dose…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks